Evidence map›Paper›PMID 34165285›Full record

ArticleBioconjugate chemistry2021

Dexamethasone and Fumaric Acid Ester Conjugate Synergistically Inhibits Inflammation and NF-κB in Macrophages.

Christopher J Genito, Meital Eckshtain-Levi, Zayda L Piedra-Quintero, Sai Archana Krovi, Abriana Kroboth, Rebeca T Stiepel, Mireia Guerau-de-Arellano, Eric M Bachelder, Kristy M Ainslie

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Christopher J GenitoDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-9044-964X
Meital Eckshtain-LeviDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Zayda L Piedra-QuinteroDivision of Medical Laboratory Science, School of Health and Rehabilitation Sciences, College of Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio 43210, United States.
Sai Archana KroviDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Abriana KrobothDivision of Medical Laboratory Science, School of Health and Rehabilitation Sciences, College of Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio 43210, United States.
Rebeca T StiepelDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Mireia Guerau-de-ArellanoDivision of Medical Laboratory Science, School of Health and Rehabilitation Sciences, College of Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio 43210, United States.
Eric M BachelderDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-8572-888X
Kristy M AinslieDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-1820-8382
University of North Carolina at Chapel Hill · USThe Ohio State University Wexner Medical Center · US

Funding

Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu VaccineR01AI141333 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BACHELDER, ERIC, TING, JENNY P · 2019 to 2023
$5.9M
BASIC IMMUNE MECHANISMST32AI007273 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TISCH, ROLAND M · 1985 to 2020
$5.6M
Biomaterials to study tolerance immune induction kineticsR01AI137525 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AINSLIE, KRISTY M · 2018 to 2022
$1.9M
NIAID NIH HHS R01 AI137525NIAID NIH HHS R01 AI141333NIAID NIH HHS T32 AI007273
6 · The paper itself

Abstract

Macrophage-mediated inflammation drives autoimmune and chronic inflammatory diseases. Treatment with anti-inflammatory agents can be an effective strategy to reduce this inflammation; however, high concentrations of these agents can have immune-dampening and other serious side effects. Synergistic combination of anti-inflammatory agents can mitigate dosing by requiring less drug. Multiple anti-inflammatory agents were evaluated in combination for synergistic inhibition of macrophage inflammation. The most potent synergy was observed between dexamethasone (DXM) and fumaric acid esters (e.g., monomethyl fumarate (MMF)). Furthermore, this combination was found to synergistically inhibit inflammatory nuclear factor κB (NF-κB) transcription factor activity. The optimal ratio for synergy was determined to be 1:1, and DXM and MMF were conjugated by esterification at this molar ratio. The DXM-MMF conjugate displayed improved inhibition of inflammation over the unconjugated combination in both murine and human macrophages. In the treatment of human donor monocyte-derived macrophages, the combination of DXM and MMF significantly inhibited inflammatory gene expression downstream of NF-κB and overall performed better than either agent alone. Further, the DXM-MMF conjugate significantly inhibited expression of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome-associated genes. The potent anti-inflammatory activity of the DXM-MMF conjugate in human macrophages indicates that it may have benefits in the treatment of autoimmune and inflammatory diseases.

Indexed as

AnimalsAnti-Inflammatory AgentsCytokinesDexamethasoneDrug SynergismFumaratesGene Expression RegulationHumansInflammationMacrophagesMiceNF-kappa BNitric OxideRAW 264.7 CellsAnti-Inflammatory AgentsCytokinesDexamethasoneFumaratesNF-kappa BNitric Oxide

Identifiers

PMID34165285
PMCPMC10372493
OpenAlexW3176979821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.